Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Neoplasms 1Hemangiosarcoma 1Glioma 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Solid Tumor 1

Interventions

belinostat 2Doxorubicin 2spartalizumab 1ribociclib 1pembrolizumab 1peginterferon alfa-2a 1cixutumumab 1balstilimab 1Radiotherapy 1RNA, Messenger 1Paclitaxel 1Ipilimumab 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Fluorouracil 1Filgrastim 1Chemotherapy, Adjuvant 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Hemangiosarcoma × balstilimab × Clear all
NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

Agenus Inc.

Phase 1 Active not recruiting
499 enrolled
GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡